Medicenna Therapeutics Corp. (MDNAF)

It posted a net loss of CA$10M. At March 31, 2023 it held CA$33.6M in cash.

Watch MDNAF in 60 seconds

Price

$0.31

+7.02% on the day · September 25, 2026

52-week range $0.23 to $1.43

What Medicenna Therapeutics Corp. does

Medicenna Therapeutics Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker MDNAF.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in CAD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2023	n/a	n/a	-CA$10M	-CA$0.16	n/a
2022	n/a	n/a	-CA$22.6M	-CA$0.42	n/a
2021	n/a	n/a	-CA$17.3M	-CA$0.35	n/a
2021	n/a	n/a	-CA$8.3M	-CA$0.26	n/a

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Medicenna Therapeutics Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

May 14, 2024
Deregistration 15-12G
May 13, 2024
Foreign issuer update 6-K
May 10, 2024
Passive stake (5% or more) SC 13G
May 10, 2024
Form POS AM filing POS AM
April 30, 2024
Foreign issuer update 6-K
April 26, 2024
Foreign issuer update 6-K
April 25, 2024
Foreign issuer update 6-K
April 22, 2024
Form AW filing AW
April 16, 2024
Form S-8 POS filing S-8 POS
April 16, 2024
Form F-3/A filing F-3/A

All filings on SEC EDGAR

Questions about MDNAF

What does Medicenna Therapeutics Corp. do?

Medicenna Therapeutics Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker MDNAF.

Is Medicenna Therapeutics Corp. profitable?

No. In fiscal 2023 it reported a net loss of CA$10M.

When did Medicenna Therapeutics Corp. last report?

Its newest filing of any kind is the deregistration from May 14, 2024.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare MDNAF with

Compare MDNAF with any company

Follow MDNAF

Get an email when Medicenna Therapeutics Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow MDNAF: get an email when it files

Where the numbers come from

Financial figures are the values Medicenna Therapeutics Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.